At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BCTX BriaCell Therapeutics Corp.
Market Closed 10-04 16:00:00 EDT
0.9842
+0.0242
+2.52%
盘后0.9781
-0.0061-0.62%
19:53 EDT
High1.03
Low0.9200
Vol1.91M
Open0.9514
D1 Closing0.9600
Amplitude11.46%
Mkt Cap35.27M
Tradable Cap25.07M
Total Shares35.84M
T/O1.88M
T/O Rate7.50%
Tradable Shares25.47M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BriaCell Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.